Inari Medical, Inc.
NARI · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 23.77 | 0.31 | -8.64 | -0.17 |
| FCF Yield | 0.81% | -0.71% | 0.26% | -0.13% |
| EV / EBITDA | 242.25 | -182.45 | 289.05 | 163.45 |
| Quality | ||||
| ROIC | 0.90% | -6.97% | 2.27% | 9.20% |
| Gross Margin | 88.03% | 88.39% | 91.06% | 90.62% |
| Cash Conversion Ratio | -21.96 | 0.48 | 2.59 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.24% | 40.03% | 75.63% | 173.47% |
| Free Cash Flow Growth | 224.26% | -302.04% | 433.74% | 56.09% |
| Safety | ||||
| Net Debt / EBITDA | -0.43 | 1.53 | -4.10 | -6.96 |
| Interest Coverage | -71.59 | -95.57 | 22.62 | 16.23 |
| Efficiency | ||||
| Inventory Turnover | 1.38 | 1.37 | 1.18 | 1.24 |
| Cash Conversion Cycle | 251.58 | 260.18 | 269.76 | 283.46 |